Systemic and Ocular Long Pentraxin 3 in Patients with Age-Related Macular Degeneration

Helene Bæk Juel; Carsten Faber; Lea Munthe Fog; Simone Bastrup-Birk; Alexander Lynge Reese-Petersen; Mads Krüger Falk; Amardeep Singh; Torben Lykke Sørensen; Peter Garred; Mogens Holst Nissen

doi:10.1371/journal.pone.0132800

Systemic and Ocular Long Pentraxin 3 in Patients with Age-Related Macular Degeneration

Helene Bæk Juel, Carsten Faber, Lea Munthe Fog, Simone Bastrup-Birk, Alexander Lynge Reese-Petersen, Mads Krüger Falk, Amardeep Singh, Torben Lykke Sørensen, Peter Garred, Mogens Holst Nissen

Department of Clinical Medicine

9 Citations (Scopus)

Abstract

Age-related macular degeneration (AMD) has been associated with both systemic and ocular alterations of the immune system. In particular dysfunction of complement factor H (CFH), a soluble regulator of the alternative pathway of the complement system, has been implicated in AMD pathogenesis. One of the ligands for CFH is long pentraxin 3 (PTX3), which is produced locally in the retinal pigment epithelium (RPE). To test the hypothesis that PTX3 is relevant to retinal immunohomeostasis and may be associated with AMD pathogenesis, we measured plasma PTX3 protein concentration and analyzed the RPE/choroid PTX3 gene expression in patients with AMD. To measure the ability of RPE cells to secrete PTX3 in vitro, polarized ARPE-19 cells were treated with activated T cells or cytokines (interferon (IFN)-gamma and/or tumor necrosis factor (TNF)-Alpha) from the basolateral side; then PTX3 protein concentration in supernatants and PTX3 gene expression in tissue lysates were quantified. Plasma levels of PTX3 were generally low and did not significantly differ between patients and controls (P=0.307). No statistically significant difference was observed between dry and exudative AMD nor was there any correlation with hsCRP or CFH genotype. The gene expression of PTX3 increased in RPE/choroid with age (P=0.0098 macular; P=0.003 extramacular), but did not differ between aged controls and AMD patients. In vitro, ARPE-19 cells increased expression of the PTX3 gene as well PTX3 apical secretions after stimulation with TNF-Alpha or activated T cells (P<0.01). These findings indicate that PTX3 expressed in the eye cannot be detected systemically and systemic PTX3 may have little or no impact on disease progression, but our findings do not exclude that locally produced PTX3 produced in the posterior segment of the eye may be part of the AMD immunopathogenesis.

Original language	English
Article number	e0132800
Journal	P L o S One
Volume	10
Issue number	7
Pages (from-to)	1-12
ISSN	1932-6203
DOIs	https://doi.org/10.1371/journal.pone.0132800
Publication status	Published - 15 Jul 2015

Access to Document

10.1371/journal.pone.0132800

Cite this

@article{7396c7964e4b4cd38bf86c3be15bfcf3,

title = "Systemic and Ocular Long Pentraxin 3 in Patients with Age-Related Macular Degeneration",

abstract = "Age-related macular degeneration (AMD) has been associated with both systemic and ocular alterations of the immune system. In particular dysfunction of complement factor H (CFH), a soluble regulator of the alternative pathway of the complement system, has been implicated in AMD pathogenesis. One of the ligands for CFH is long pentraxin 3 (PTX3), which is produced locally in the retinal pigment epithelium (RPE). To test the hypothesis that PTX3 is relevant to retinal immunohomeostasis and may be associated with AMD pathogenesis, we measured plasma PTX3 protein concentration and analyzed the RPE/choroid PTX3 gene expression in patients with AMD. To measure the ability of RPE cells to secrete PTX3 in vitro, polarized ARPE-19 cells were treated with activated T cells or cytokines (interferon (IFN)-gamma and/or tumor necrosis factor (TNF)-Alpha) from the basolateral side; then PTX3 protein concentration in supernatants and PTX3 gene expression in tissue lysates were quantified. Plasma levels of PTX3 were generally low and did not significantly differ between patients and controls (P=0.307). No statistically significant difference was observed between dry and exudative AMD nor was there any correlation with hsCRP or CFH genotype. The gene expression of PTX3 increased in RPE/choroid with age (P=0.0098 macular; P=0.003 extramacular), but did not differ between aged controls and AMD patients. In vitro, ARPE-19 cells increased expression of the PTX3 gene as well PTX3 apical secretions after stimulation with TNF-Alpha or activated T cells (P<0.01). These findings indicate that PTX3 expressed in the eye cannot be detected systemically and systemic PTX3 may have little or no impact on disease progression, but our findings do not exclude that locally produced PTX3 produced in the posterior segment of the eye may be part of the AMD immunopathogenesis.",

author = "Juel, {Helene B{\ae}k} and Carsten Faber and Fog, {Lea Munthe} and Simone Bastrup-Birk and Reese-Petersen, {Alexander Lynge} and Falk, {Mads Kr{\"u}ger} and Amardeep Singh and S{\o}rensen, {Torben Lykke} and Peter Garred and Nissen, {Mogens Holst}",

year = "2015",

month = jul,

day = "15",

doi = "10.1371/journal.pone.0132800",

language = "English",

volume = "10",

pages = "1--12",

journal = "PLoS Computational Biology",

issn = "1932-6203",

publisher = "Public Library of Science",

number = "7",

}

TY - JOUR

T1 - Systemic and Ocular Long Pentraxin 3 in Patients with Age-Related Macular Degeneration

AU - Juel, Helene Bæk

AU - Faber, Carsten

AU - Fog, Lea Munthe

AU - Bastrup-Birk, Simone

AU - Reese-Petersen, Alexander Lynge

AU - Falk, Mads Krüger

AU - Singh, Amardeep

AU - Sørensen, Torben Lykke

AU - Garred, Peter

AU - Nissen, Mogens Holst

PY - 2015/7/15

Y1 - 2015/7/15

N2 - Age-related macular degeneration (AMD) has been associated with both systemic and ocular alterations of the immune system. In particular dysfunction of complement factor H (CFH), a soluble regulator of the alternative pathway of the complement system, has been implicated in AMD pathogenesis. One of the ligands for CFH is long pentraxin 3 (PTX3), which is produced locally in the retinal pigment epithelium (RPE). To test the hypothesis that PTX3 is relevant to retinal immunohomeostasis and may be associated with AMD pathogenesis, we measured plasma PTX3 protein concentration and analyzed the RPE/choroid PTX3 gene expression in patients with AMD. To measure the ability of RPE cells to secrete PTX3 in vitro, polarized ARPE-19 cells were treated with activated T cells or cytokines (interferon (IFN)-gamma and/or tumor necrosis factor (TNF)-Alpha) from the basolateral side; then PTX3 protein concentration in supernatants and PTX3 gene expression in tissue lysates were quantified. Plasma levels of PTX3 were generally low and did not significantly differ between patients and controls (P=0.307). No statistically significant difference was observed between dry and exudative AMD nor was there any correlation with hsCRP or CFH genotype. The gene expression of PTX3 increased in RPE/choroid with age (P=0.0098 macular; P=0.003 extramacular), but did not differ between aged controls and AMD patients. In vitro, ARPE-19 cells increased expression of the PTX3 gene as well PTX3 apical secretions after stimulation with TNF-Alpha or activated T cells (P<0.01). These findings indicate that PTX3 expressed in the eye cannot be detected systemically and systemic PTX3 may have little or no impact on disease progression, but our findings do not exclude that locally produced PTX3 produced in the posterior segment of the eye may be part of the AMD immunopathogenesis.

AB - Age-related macular degeneration (AMD) has been associated with both systemic and ocular alterations of the immune system. In particular dysfunction of complement factor H (CFH), a soluble regulator of the alternative pathway of the complement system, has been implicated in AMD pathogenesis. One of the ligands for CFH is long pentraxin 3 (PTX3), which is produced locally in the retinal pigment epithelium (RPE). To test the hypothesis that PTX3 is relevant to retinal immunohomeostasis and may be associated with AMD pathogenesis, we measured plasma PTX3 protein concentration and analyzed the RPE/choroid PTX3 gene expression in patients with AMD. To measure the ability of RPE cells to secrete PTX3 in vitro, polarized ARPE-19 cells were treated with activated T cells or cytokines (interferon (IFN)-gamma and/or tumor necrosis factor (TNF)-Alpha) from the basolateral side; then PTX3 protein concentration in supernatants and PTX3 gene expression in tissue lysates were quantified. Plasma levels of PTX3 were generally low and did not significantly differ between patients and controls (P=0.307). No statistically significant difference was observed between dry and exudative AMD nor was there any correlation with hsCRP or CFH genotype. The gene expression of PTX3 increased in RPE/choroid with age (P=0.0098 macular; P=0.003 extramacular), but did not differ between aged controls and AMD patients. In vitro, ARPE-19 cells increased expression of the PTX3 gene as well PTX3 apical secretions after stimulation with TNF-Alpha or activated T cells (P<0.01). These findings indicate that PTX3 expressed in the eye cannot be detected systemically and systemic PTX3 may have little or no impact on disease progression, but our findings do not exclude that locally produced PTX3 produced in the posterior segment of the eye may be part of the AMD immunopathogenesis.

U2 - 10.1371/journal.pone.0132800

DO - 10.1371/journal.pone.0132800

M3 - Journal article

C2 - 26176960

SN - 1932-6203

VL - 10

SP - 1

EP - 12

JO - PLoS Computational Biology

JF - PLoS Computational Biology

IS - 7

M1 - e0132800

ER -

Systemic and Ocular Long Pentraxin 3 in Patients with Age-Related Macular Degeneration

Abstract

Access to Document

Fingerprint

Cite this